Patient-Reported Outcomes of COVID-19 Vaccine Breakthrough Infection–Associated Changes in Glucose Control in Subjects With Type 1 Diabetes (PRO-VACS 2 Study)

14 november 2022
door American Diabetes Association - Care

Despite the effectiveness of mRNA vaccines in preventing severe coronavirus disease 2019 (COVID-19) (1), infections (particularly with Omicron variant) occur in vaccinated individuals (2), especially in the case of hyperglycemia (3). Although COVID-19–related inflammation, even in its mild forms, could increase glycemia, glucose control during breakthrough infection in type 1 diabetes (T1D) has not been studied so far. The aim of this study is the assessment of short-term COVID-19 effects on glucose variability in fully vaccinated patients with T1D.

Bekijk het originele bericht

Patient-Reported Outcomes of COVID-19 Vaccine Breakthrough Infection–Associated Changes in Glucose Control in Subjects With Type 1 Diabetes (PRO-VACS 2 Study)

Wellicht vindt u dit ook interessant

Meld u aan voor de maandelijkse nieuwsbrief

Categorieën

Patiëntvoorbeelden m.b.t. vergoeding

Voeg je koptekst hier toe

Vergoeding diabetesmiddelen